Aziz Kashif, Shahbaz Amir, Zarghamravanbakhsh Paria, Ahmed Syed Ijlal, Sachmechi Issac
Internal Medicine, Icahn School of Medicine at Mount Sinai Queen Hospital Center, New York, USA.
Endocrinology, Icahn School of Medicine at Mount Sinai Queen Hospital Center, New York, USA.
Cureus. 2018 Jun 13;10(6):e2801. doi: 10.7759/cureus.2801.
Albiglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist administered by weekly injection. Albiglutide-treated patients experience incidences of adverse effects, including cardiovascular, renal, and gastrointestinal symptoms and injection-site reactions. We report the first case of generalized edema induced by albiglutide. We present a 35-year-old female with type-2 diabetes. She developed generalized edema after the start of albiglutide. Her physical examination and all the laboratory tests, including thyroid function tests, albumin level test, and renal function test were unremarkable, and did not explain her generalized edema. Later on, her albiglutide was discontinued, which lead to the resolution of her edema. We conclude that her generalized edema could be due to a possible side effect of albiglutide.
阿必鲁肽是一种长效胰高血糖素样肽-1（GLP-1）受体激动剂，通过每周注射给药。接受阿必鲁肽治疗的患者会出现不良反应，包括心血管、肾脏和胃肠道症状以及注射部位反应。我们报告了首例由阿必鲁肽引起的全身性水肿病例。我们介绍了一名35岁的2型糖尿病女性。她在开始使用阿必鲁肽后出现了全身性水肿。她的体格检查以及所有实验室检查，包括甲状腺功能检查、白蛋白水平检查和肾功能检查均无异常，无法解释她的全身性水肿。后来，她停用了阿必鲁肽，水肿随之消退。我们得出结论，她的全身性水肿可能是阿必鲁肽的一种副作用所致。
